Original ArticleTranslational OncologyMulti-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance)
Keywords
Cited by (0)
Disclosure: Dr. Hirsch reports advisory board participation for Genentech/Roche, Bristol-Myers Squibb, AstraZeneca, Merck, Novartis, Daiichi, Amgen, OncoCyte, Eli Lilly/Loxo, and Boehringer Ingelheim outside of the submitted work. Dr. Govindan reports receiving personal fees from Inivata, Pfizer, AstraZeneca, Genentech, Millennium Pharmaceuticals, AbbVie, F. Hoffman La-Roche, NeoHealth, Janssen, Bristol-Myers Squibb, Eli Lilly, Roche, Nektar, Merck, Celgene, Janssen, Partner Therapeutics, GlaxoSmithKline, Jounce, Amgen, Achilles, and GenePlus outside of the submitted work. Dr. Merrick reports receiving grants from Bristol-Myers Squibb; and personal fees from Genentech and Roche outside of the submitted work. Dr. Bueno reports receiving grants from Genentech, Roche, Merck, Verastem, Epizyme, MedGenome, Siemens, and Gritstone outside of the submitted work. In addition, Dr. Bueno has four patents through the Brigham and Women’s Hospital (no royalties to date) and equity in a new start-up company, Navigation Sciences outside of the submitted work. The remaining authors declare no conflict of interest.